Skip to main content

Chanelle Pharma

The deal

Investing in a leading European Animal & Human Health generic pharmaceuticals business


Deal size, April 2024

Fund IV & V

Current investment

The teams

Management Team

Chair: Carsten Hellmann

The story

Chanelle Pharma, founded in 1985, is Ireland’s largest manufacturer of veterinary and medical generic pharmaceuticals, serving blue-chip customers globally.

The company provides a full-service offering to its customers, including research and development, registration, production and distribution of generic veterinary and medical pharmaceuticals.

Exponent acquired the business from its founder Michael J Burke in 2024 and has partnered with Carsten Hellmann as Chair. We will work with Carsten and the incumbent management team to grow the existing product portfolio and invest in the business’ commercial capabilities, to solidify Chanelle’s leading position in its end-markets.

Chanelle operates in large and resilient verticals with high barriers to entry and switching costs. Against this attractive backdrop, we were attracted to the business by its diversified product portfolio, well-invested infrastructure, deep relationships with customers, and track record of delivering product innovation within highly regulated environments.